Fresenius Kabi

Fresenius Kabi AG is a global healthcare company focused on providing lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition, primarily for critically and chronically ill patients. The company offers a wide range of products, including blood volume substitutes, intravenous (I.V.) solutions, medical devices, and parenteral and enteral nutrition products. Its portfolio comprises generic drugs, such as anaesthetics, analgesics, and anti-infectives, as well as oncology drugs and products for blood collection and processing. Additionally, Fresenius Kabi develops biosimilar drugs targeting autoimmune diseases and specializes in complex biopharmaceuticals, ensuring comprehensive support for medical professionals in managing patient care.

Michael Sen

President and CEO

4 past transactions

Fenwal

Acquisition in 2012
Fenwal is a pioneer and global leader in the development of products that improve the safety and availability of blood. Their products help shape the practice of transfusion medicine, making life-saving blood therapies available to the medical professionals and patients worldwide who rely on them.

Ribbon

Acquisition in 2007
Ribbon is engages in the manufacture and sale of bulk active ingredients for the pharmaceutical industry. It offers betalactam antibiotics with a range of specialized products, such as semi-synthetic penicillins and cephalosporin; and B-Lactamase inhibitor.

Laboratorio Sanderson

Acquisition in 2007
Laboratorio Sanderson is a pharmaceutical company, manufactures, commercializes, and distributes injectable medications and products. It offers large volume parenteral (LVP)solutions, such as electrolytes, dextrose, sodium bicarbonate, lactated ringer, plasmatic expanders, osmotic diuretics, and solutions for peritoneal dialysis; and small volume parenteral (SVP) solutions, such as antibiotics, analgesics, narcotic-analgesics, anti-inflammatories, anesthetics, tranquilizers, anticoagulants, hypnotics, corticoids, and hormones, as well as antianxiety agents/amnestics/anticonvulsants, antihistamines, and neuromuscular blocking agents. The company’s SVP solutions also include corticosteroids, diuretics, cardiac glycosides, dextrose and vitamin therapy, calcium supplements, anti-arrhythmics/antihypertensives, adrenergics, inotropic agents, coronary vasodilators, antispasmodics/anticholinergics, antimyasthenics, antiemetics, antiasthmatics/bronchodilators, uterine relaxants, electrolyte replenishers, oxitocics, antihemorrhagic products, antibacterials, antipsychoticsanabolic steroids, and alkalizers.

Labesfal - Laboratórios Almiro

Acquisition in 2005
Labesfal - Laboratórios Almiro is manufactures and markets generic and intravenously administered drugs for therapeutic areas. The company’s products are used in the treatment of anti-infective, cardiovascular, analgesic, antipyretic, gastroenterologic, anti-histamine, and central nerves system related diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.